IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis

被引：39

作者：

Shimizu, T. ^{[1
,2
]}

Koga, T. ^{[1
,3
]}

Furukawa, K. ^{[1
]}

Horai, Y. ^{[4
]}

Fujikawa, K. ^{[5
]}

Okada, A. ^{[6
]}

Okamoto, M. ^{[1
]}

Endo, Y. ^{[1
]}

Tsuji, S. ^{[1
]}

Takatani, A. ^{[1
]}

Umeda, M. ^{[1
]}

Fukui, S. ^{[1
]}

Sumiyoshi, R. ^{[1
,2
]}

Kawashiri, S. -Y ^{[1
]}

Iwamoto, N. ^{[1
]}

Igawa, T. ^{[1
]}

Ichinose, K. ^{[1
]}

Tamai, M. ^{[1
]}

Sakamoto, N. ^{[7
]}

Nakamura, H. ^{[1
]}

Origuchi, T. ^{[1
,8
]}

Mukae, H. ^{[7
]}

Kuwana, M. ^{[9
]}

Kawakami, A. ^{[1
]}

机构：

[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Div Adv Prevent Med Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[2] Nagasaki Univ Hosp, Clin Res Ctr, Nagasaki, Japan

[3] Nagasaki Univ, Grad Sch Biomed Sci, Ctr Bioinformat & Mol Med, Nagasaki, Japan

[4] Natl Hosp Org Nagasaki Med Ctr, Dept Rheumatol, Omura, Japan

[5] Isahaya Gen Hosp, Japan Community Hlth Care Org, Dept Rheumatol, Isahaya, Japan

[6] Japan Red Cross Nagasaki Genbaku Hosp, Dept Rheumatol, Nagasaki, Japan

[7] Nagasaki Univ, Grad Sch Biomed Sci, Dept Resp Med, Nagasaki, Japan

[8] Nagasaki Univ, Grad Sch Biomed Sci, Dept Rehabil Sci, Nagasaki, Japan

[9] Nippon Med Sch, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan

来源：

JOURNAL OF INTERNAL MEDICINE | 2021年 / 289卷 / 02期

关键词：

anti-MDA5; antibody; biomarkers; dermatomyositis; interleukin-15; polymyositis; rapidly progressive interstitial lung disease; DERMATOMYOSITIS SINE MYOSITIS; AMYOPATHIC DERMATOMYOSITIS; JAPANESE PATIENTS; ANTI-MDA5; ANTIBODY; GENE; POLYMYOSITIS; CELLS; AUTOANTIBODIES; ASSOCIATION; FERRITIN;

D O I：

10.1111/joim.13154

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Polymyositis/dermatomyositis (PM/DM) is an autoimmune disease that is sometimes complicated with rapidly progressive interstitial lung disease (RPILD). However, serum and lung biomarkers that can predict RPILD development remain unclear. Objectives To determine potential serum and lung biomarkers that can predict RPILD development in patients with PM/DM-ILD. Methods In total, 49 patients with PM/DM-ILD were enrolled. We measured the serum levels of 41 cytokines/chemokines, ferritin and anti-MDA5 antibody, compared them between the RPILD (n = 23) and non-RPILD (n = 26) groups, and ranked them by their importance through random forest analysis. To distinguish the two groups, we determined biomarker combinations by logistic regression analysis. We also measured the bronchoalveolar lavage fluid (BALF) levels of 41 cytokines/chemokines. Using immunohistochemistry, we examined IL-15 expression in lung tissues. The IL-15 production was also investigated using A549 and BEAS-2B cells. Results The RPILD group had significantly higher IL-15, IL-1RA, IL-6, CXCL10, VCAM-1, anti-MDA5 antibody and ferritin serum levels than the non-RPILD group, but it had a significantly low CCL22 level. Meanwhile, anti-MDA5 antibody, IL-15, CXCL8, CCL22, IL-1RA and ferritin were the best combination to distinguish the two groups. IL-15 and CCL22 were also predictive marker for RPILD development in anti-MDA5 antibody-positive patients. Additionally, the RPILD group had significantly high IL-15 levels in BALF. The lung tissues expressed IL-15, which increased after cytokine stimulation in the A549 cells. Conclusion This study identified a combination of biomarkers predicting PM/DM-RPILD progression, and IL-15 is an important cytokine for predicting RPILD development and reflecting ILD severity.

引用

页码：206 / 220

页数：15

共 35 条

[1] Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis [J].